NEW YORK--(BUSINESS WIRE)--Jul 16, 2025--
Paige, a leader in next-generation AI technology, today announced the release of PRISM2, its most advanced slide-level foundation model to date. PRISM2 is designed to advance large language models (LLM) by enabling them to understand pathology images, connecting visual patterns with the clinical language used by clinicians to unlock novel capabilities. Built for versatility across diverse settings, PRISM2 acts as a building block that supports a wide range of applications in both clinical practice and pharmaceutical research, including diagnostics, biomarker prediction, and multi-modal patient outcome modeling.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716906798/en/
Developed in collaboration with Microsoft Research and expanding on the original PRISM model, PRISM2 was developed by building on Virchow2, the company’s state-of-the-art pathology foundation model, PRISM2 is trained on more than 2.3 million H&E-stained whole-slide images spanning hundreds of thousands of patient cases. Each slide is paired with its corresponding clinical report, grounding the model in the language of real-world diagnosis and enhancing its ability to generate clinically relevant insights across diverse populations, tissue types, and cancers. The result is a multimodal AI model capable of capturing both fine-grained cellular detail and whole-slide context.
PRISM2 was built with direct compatibility for modern language models, including a version integrated with Microsoft Phi-3, enabling more efficient multimodal deployment. This unique design bridges vision and text, powering natural language responses in pathology and delivering performance that surpasses previous models, particularly in rare cancer types and low-sample-size scenarios.
“PRISM2 represents a defining moment in digital pathology and AI. By combining the versatility of Virchow2 with rich clinical ground truths and seamless LLM integration, we’ve created a model that doesn’t just analyze tissue, it contextualizes morphological patterns with diagnostic cues,” said Siqi Liu, VP of AI Science at Paige. “This unlocks new capabilities in reporting, screening, and outcome prediction, allowing AI to become a true partner in diagnosis, research, and treatment.”
Benchmarks demonstrate that PRISM2 outperforms its predecessor and other slide-level foundation models across a wide range of diagnostic and biomarker prediction tasks. It delivers strong zero-shot performance on tasks such as tumor detection and can instantly generate concise, clinician-aligned reports, streamlining workloads, reducing turnaround times, and improving consistency in diagnosis.
For pharmaceutical and life sciences partners, PRISM2 offers a flexible tool to identify patient cohorts, predict outcomes, and accelerate biomarker discovery, even in low-data environments where traditional AI approaches often fall short.
PRISM2 is now available for licensing and enterprise integration, offering access to general-purpose slide-level embeddings and the ability to adapt the model for specialized applications.
It is also integrated into Alba™*, Paige’s clinical co-pilot, where it enables agentic workflows including AI-assisted triage, case review, and multimodal decision support.
“Our mission is to transform how cancer is diagnosed and treated by building intelligent, adaptable systems that integrate seamlessly into clinical and research environments,” said Razik Yousfi, CEO and CTO of Paige. “With PRISM2, we are setting a new industry standard, not only in performance, but in usability and flexibility. This is the model that will drive a wave of innovation in pathology and oncology.”
---
*Alba™ leverages next-generation generative AI to automate routine tasks, analyze pathology images, and provide prompt clinical insights, all within an intuitive, interactive interface. The content generated by Alba is for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Alba is currently a Beta release and has not yet been made commercially available by Paige.
About Paige
Paige is pushing the boundaries of AI to solve cancer’s most critical issues, revolutionizing cancer care with next-generation technology. By leveraging exclusive access to millions of digitized pathology slides, clinical reports, and genomic data, Paige gains a holistic understanding of cancer, encompassing diverse factors such as gender, race, ethnicity, and geographical regions. This comprehensive data enables Paige to create advanced AI solutions that redefine cancer detection, diagnosis, and treatment. With a unique, intricate understanding of tissue, Paige sets new standards in precision diagnostics, earning the distinction of being the first FDA-cleared AI application in pathology. Paige has also developed the first million-slide foundation model for cancer, continuing to lead the way in uncovering novel insights and transforming them into life-changing products. For more information, visit www.paige.ai.
PRISM2 combines whole-slide images and clinical language using a large language model to generate diagnostic insights, summaries, and answer both simple and complex diagnostic questions.
